PMID- 17729191
OWN - NLM
STAT- MEDLINE
DCOM- 20071029
LR  - 20220408
IS  - 0720-4299 (Print)
IS  - 0720-4299 (Linking)
VI  - 75
IP  - 9
DP  - 2007 Sep
TI  - [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in 
      neurological and psychiatric disorders--current evidence and preliminary 
      recommendations].
PG  - 515-27
AB  - Elevated concentration of total homocysteine (Hcy) in plasma (> 12 micromol/l) is 
      a risk factor for several diseases of the central nervous system. Epidemiological 
      studies have shown a dose-dependent relationship between concentrations of Hcy 
      and the risk for neurodegenerative diseases. Hcy is a marker for B-vitamin 
      deficiency (folate, B12, B6). Hyperhomocysteinemia (HHcy) causes hypomethylation 
      which is an important mechanism that links Hcy to dementia. Supplementation with 
      vitamins B aims at reducing the risk of neurodegenerative diseases. Current 
      evidence suggests that Hcy-lowering treatment has a positive effect for the 
      secondary and primary prevention of stroke. HHcy is very common in patients with 
      Parkinson disease particularly those who receive L-dopa treatment. Furthermore, a 
      positive association has been reported between HHcy and multiple sclerosis. 
      Moreover, HHcy and vitamin B deficiency are reported to have a causal role in 
      depression, and epilepsy. In addition several anti-epileptic drugs cause 
      secondary HHcy. Therefore, sufficient intakes of the vitamins are recommended for 
      patients who have already developed neuropsychiatric diseases. Vitamin B 
      deficiency should be suspected in children with development disorders, failure to 
      thrive and unexplained neurological manifestations. Elderly people are also an 
      important at-risk group where vitamin B deficiency and HHcy have been linked to 
      neurodegenerative diseases. Treatment with folate, B12, and B6 can improve 
      cerebral function. Preventive vitamin B supplementation and sufficient intake 
      seem very important for secondary and primary prevention of neuropsychiatric 
      disorders, especially in subjects with a low intake or status of the vitamins.
FAU - Herrmann, W
AU  - Herrmann W
AD  - Institut fur Klinische Chemie und Laboratoriumsmedizin, Universitatsklinikum des 
      Saarlandes, Kirrberger Strasse, Gebaude 57, 66421 Homburg. 
      prof.wolfgang.herrmann@uni-klinikum-saarland.de
FAU - Lorenzl, S
AU  - Lorenzl S
FAU - Obeid, R
AU  - Obeid R
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hyperhomocysteinamie und B-Vitaminmangel bei neurologischen und psychiatrischen 
      Erkrankungen--Aktueller Kenntnisstand und vorlaufige Empfehlungen.
PL  - Germany
TA  - Fortschr Neurol Psychiatr
JT  - Fortschritte der Neurologie-Psychiatrie
JID - 8103137
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 935E97BOY8 (Folic Acid)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Aged
MH  - Central Nervous System/metabolism
MH  - Child
MH  - Dietary Supplements
MH  - Folic Acid/therapeutic use
MH  - Homocysteine/metabolism/physiology
MH  - Humans
MH  - Hyperhomocysteinemia/*blood
MH  - Mental Disorders/blood/epidemiology/*physiopathology
MH  - Nervous System Diseases/blood/*physiopathology
MH  - Parkinson Disease/metabolism
MH  - Risk Factors
MH  - Vitamin B 12/therapeutic use
MH  - Vitamin B Deficiency/*blood
RF  - 0
EDAT- 2007/08/31 09:00
MHDA- 2007/10/30 09:00
CRDT- 2007/08/31 09:00
PHST- 2007/08/31 09:00 [pubmed]
PHST- 2007/10/30 09:00 [medline]
PHST- 2007/08/31 09:00 [entrez]
AID - 10.1055/s-2007-980112 [doi]
PST - ppublish
SO  - Fortschr Neurol Psychiatr. 2007 Sep;75(9):515-27. doi: 10.1055/s-2007-980112.